Skip to content

Clinical trials

Phase 3 Non-alcoholic Fatty Liver Disease trials in Taiwan

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Non-alcoholic Fatty Liver Disease Phase: Phase 3 Country / region: Taiwan Clear all

11 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20173
20211
20231
20242
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting5
Terminated4
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
89bio, Inc.2
Gilead Sciences2
GlaxoSmithKline2
Akero Therapeutics, Inc1
Eli Lilly and Company1
National Taiwan University Hospital1
Novo Nordisk A/S1
Tobira Therapeutics, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Non-alcoholic Fatty Liver Disease11
Fatty Liver4
Liver Diseases3
Digestive System Diseases2
Fibrosis2
Metabolic Diseases2
Acquired Immunodeficiency Syndrome1
HIV Infections1
Hepatitis B1
Hepatitis C1

Trials

Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.